Universal Biosensors Inc Asset Resilience Ratio
Universal Biosensors Inc asset resilience ratio. Universal Biosensors Inc (UBI) has an Asset Resilience Ratio of 14.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Universal Biosensors Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Universal Biosensors Inc (2007–2024)
Asset resilience ratio of Universal Biosensors Inc from 2007 to 2024. This chart shows how Universal Biosensors Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Universal Biosensors Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Universal Biosensors Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see UBI current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.20 Million | 14.72% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.20 Million | 14.72% |
Asset Resilience Insights
- Moderate Liquidity: Universal Biosensors Inc has 14.72% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Universal Biosensors Inc Industry Peers by Asset Resilience Ratio
Compare Universal Biosensors Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 5.11% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
Universal Biosensors Inc Asset Resilience Ratio by Year (2007–2024)
Universal Biosensors Inc asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Universal Biosensors Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.06% | AU$8.54 Million ≈ $6.05 Million |
AU$25.84 Million ≈ $18.28 Million |
-1.22pp |
| 2023-12-31 | 34.28% | AU$10.28 Million ≈ $7.27 Million |
AU$29.97 Million ≈ $21.21 Million |
-22.01pp |
| 2022-12-31 | 56.30% | AU$25.98 Million ≈ $18.38 Million |
AU$46.15 Million ≈ $32.65 Million |
+21.87pp |
| 2021-12-31 | 34.42% | AU$15.32 Million ≈ $10.84 Million |
AU$44.50 Million ≈ $31.49 Million |
-7.37pp |
| 2020-12-31 | 41.79% | AU$23.56 Million ≈ $16.67 Million |
AU$56.38 Million ≈ $39.89 Million |
-6.45pp |
| 2019-12-31 | 48.24% | AU$30.23 Million ≈ $21.39 Million |
AU$62.66 Million ≈ $44.34 Million |
+31.39pp |
| 2018-12-31 | 16.86% | AU$11.80 Million ≈ $8.35 Million |
AU$69.98 Million ≈ $49.51 Million |
-39.94pp |
| 2017-12-31 | 56.80% | AU$26.27 Million ≈ $18.59 Million |
AU$46.26 Million ≈ $32.73 Million |
+15.98pp |
| 2016-12-31 | 40.81% | AU$20.40 Million ≈ $14.44 Million |
AU$49.99 Million ≈ $35.37 Million |
+40.63pp |
| 2011-12-31 | 0.18% | AU$83.34K ≈ $58.97K |
AU$45.22 Million ≈ $31.99 Million |
-4.73pp |
| 2007-12-31 | 4.92% | AU$3.14 Million ≈ $2.22 Million |
AU$63.86 Million ≈ $45.18 Million |
-- |
About Universal Biosensors Inc
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of… Read more